In vitro and in vivo evaluation of hypericin for photodynamic therapy of equine sarcoids.
Authors: Martens A, de Moor A, Waelkens E, Merlevede W, De Witte P
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary Hypericin, a naturally occurring photosensitising compound, has demonstrated promising cytotoxic effects against equine sarcoid cells in laboratory conditions, with phototoxicity comparable to that seen in human cancer cell lines and critically dependent on light energy dosage rather than cell type variation. In a clinical case involving three sarcoids in a donkey, repeated intratumoural hypericin injections combined with daily light exposure over 25 days produced an 81% reduction in tumour volume, improving further to 90% reduction two months post-treatment—a notable result for a condition where recurrence remains problematic regardless of treatment modality. Photodynamic therapy using hypericin represents a potentially less invasive alternative to current sarcoid management strategies (surgery, immunotherapy, laser ablation), which carry risks of tumour seeding, variable efficacy rates, and significant tissue trauma. Whilst the in vitro and small clinical findings are encouraging, farriers and equine practitioners should note that this 2000 paper constitutes early-stage research; considerably more clinical evidence across larger sample sizes and diverse sarcoid presentations would be required before this approach could be integrated into routine practice. Further investigation into optimal injection protocols, light wavelengths, treatment intervals, and long-term recurrence rates remains essential to determine whether hypericin-based photodynamic therapy might offer a genuine clinical advantage in managing this prevalent equine tumour.
Read the full abstract on PubMed
Practical Takeaways
- •Hypericin-based photodynamic therapy shows promising early results for equine sarcoid treatment with substantial tumor volume reduction, though more clinical trials are needed before practice adoption
- •Treatment protocol involved four intratumoural injections followed by daily illumination over 25 days, suggesting this is a time-intensive procedure requiring commitment
- •As a non-invasive approach, this technique could offer an alternative to traditional surgical or other invasive sarcoid treatments, potentially reducing complications and recovery time
Key Findings
- •In vitro phototoxic effects of hypericin were comparable between equine and human cell lines and significantly influenced by energy density used
- •In vivo treatment of three equine sarcoids with hypericin photodynamic therapy achieved 81% tumor volume reduction at end of therapy and 90% reduction at 2 months post-treatment
- •Hypericin photodynamic therapy demonstrates potential as a non-invasive treatment modality for equine sarcoids